title: Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
abstract: Dermatologists are in a key position to treat the manifestations of polycystic ovary syndrome (PCOS). The management of PCOS should be tailored to each woman's specific goals, reproductive interests, and particular constellation of symptoms. Therefore, a multidisciplinary approach is recommended. In part II of this continuing medical education article, we present the available safety and efficacy data regarding treatments for women with acne, hirsutism, and androgenetic alopecia. Therapies discussed include lifestyle modification, topical therapies, combined oral contraceptives, antiandrogen agents, and insulin-sensitizing drugs. Treatment recommendations are made based on the current available evidence.
authors.affiliation: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Buzney
authors.affiliation: Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
authors.forename: Johanna
authors.initials: J
authors.lastname: Sheu
authors.affiliation: Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: Catherine
authors.initials: C
authors.lastname: Buzney
authors.affiliation: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: rreynold@bidmc.harvard.edu.
authors.forename: Rachel V
authors.initials: RV
authors.lastname: Reynolds
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000152:Acne Vulgaris / Q000188:drug therapy*; D000505:Alopecia / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use*; D003880:Dermatology; D005260:Female; D018120:Finasteride / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006628:Hirsutism / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D008687:Metformin / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000628:therapy*; D013148:Spironolactone / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D003277:Contraceptives, Oral, Combined; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D045162:Thiazolidinediones; D013148:Spironolactone; D018120:Finasteride; D005485:Flutamide; D008687:Metformin
keywords: acne; androgenetic alopecia; combined oral contraceptive pills; cyproterone acetate; drospirenone; hirsutism; insulin-sensitizing drugs; polycystic ovary syndrome; spironolactone